3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tobacco Use Disorder
1
Stomach Neoplasms
1
Smoking Cessation
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Oropharyngeal Neoplasms
1
Nasopharyngeal Neoplasms
1
Mouth Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Liver Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
36
Capecitabine
28
Trastuzumab
23
Paclitaxel
22
Surveys and Questionnaires
20
Cyclophosphamide
20
Gemcitabine
18
Docetaxel
18
Carboplatin
15
Nivolumab
14
Methods
14
Magnetic Resonance Spectroscopy
13
Early Intervention, Educational
13
Bevacizumab
13
Interviews as Topic
12
Blood Specimen Collection
12
fludarabine
11
Standard of Care
11
Irinotecan
11
olaparib
10
durvalumab
10
Specimen Handling
10
Psychiatric Rehabilitation
10
palbociclib
9
aldesleukin
9
Taxes
9
Fulvestrant
9
Fluorouracil
9
Exercise
9
Drug Therapy
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Nicotine Replacement Therapy
×
Gastrointestinal
×
Clear all
NCT04899492
2024-11-07
RESPIRE
Institut Cancerologie de l'Ouest
Phase NA
Terminated
22 enrolled